EHNA

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by The Nth User (talk | contribs) at 23:56, 4 June 2019 (→‎References: Replaced one category with subcategory). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

EHNA
Identifiers
  • 3-(6-aminopurin-9-yl)nonan-2-ol
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H23N5O
Molar mass277.365 g/mol g·mol−1
3D model (JSmol)
  • CCCCCCC(C(C)O)n1cnc2c1ncnc2N
  • InChI=1S/C14H23N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h8-11,20H,3-7H2,1-2H3,(H2,15,16,17)
  • Key:IOSAAWHGJUZBOG-UHFFFAOYSA-N
  (verify)

EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine) is a potent adenosine deaminase inhibitor,[1] which also acts as a phosphodiesterase inhibitor that selectively inhibits phosphodiesterase type 2 (PDE2).[2][3]

References

  1. ^ "Sigma Aldrich". Retrieved 16 January 2013.
  2. ^ Podzuweit, T; Nennstiel, P; Muller, A (1995). "Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine". Cell Signal. 7 (7): 733–8. doi:10.1016/0898-6568(95)00042-N. PMID 8519602.
  3. ^ Méry, PF; Pavoine, C; Pecker, F; Fischmeister, R (1995). "Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes". Mol Pharmacol. 48 (1): 121–130. PMID 7623766.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=EHNA&oldid=900335244"